Search results
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Giuseppe Rosano and Dr Stephen Greene discuss the implementation of guideline-directed medical therapy (GDMT) in heart failure and strategies to overcome clinical inertia.
View more
Added:
1 month ago
Source:
Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes…
View more
Added:
3 weeks ago
Source:
Arrhythmia and Electrophysiology Review
For patients with heart failure (HF) and left bundle-branch block (LBBB), left bundle-branch pacing (LBBP) has been proposed as an alternative to the standard biventricular pacing (BiVP).¹ A new randomised trial, HeartSync-LBBP, has found that LBBP leads to superior long-term clinical outcomes compared with BiVP in this patient population.²MethodologyThe HeartSync-LBBP trial was a multicentre,…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the VICTOR trial suggests that in compensated patients with heart failure and reduced ejection fraction (HFrEF), vericiguat may reduce the overall burden of worsening heart failure (HF) when outpatient events are included alongside hospitalisations.¹Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway,…
View more
Added:
1 year ago
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.Dr Marat…
View more
Added:
2 weeks ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more
Added:
1 year ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home…
View more